SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SAN DIEGO and TORONTO, Aug. 03, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the Canaccord Genuity 37th Annual Growth Conference on Thursday, August 10th, 2017 at 11:30 a.m. ET at the Intercontinental Hotel, Boston, MA.
Dr. Rice will provide a corporate overview of the Company’s recent activities and strategic direction.
| Time: | 11:30 a.m. ET | ||||
| Date: | Thursday, August 10, 2017 | ||||
| Location: | Intercontinental Hotel, Boston, MA | ||||
A live webcast of the Aptose presentation will be accessible by visiting:
http://wsw.com/webcast/canaccord26/apto
The webcast will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Greg Chow, CFO 647-479-9828 [email protected] SMP Communications Susan Pietropaolo 201-923-2049 [email protected]
